Evidence map›Paper›PMID 34660476›Full record

ArticleFrontiers in pediatrics2021

Efficacy of Sirolimus in Patients Requiring Tracheostomy for Life-Threatening Lymphatic Malformation of the Head and Neck: A Report From the European Reference Network.

Annegret Holm, Maroeska Te Loo, Leo Schultze Kool, Päivi Salminen, Veronica Celis, Eulalia Baselga, Sophie Duignan, Veronika Dvorakova, Alan D Irvine, Laurence M Boon and 5 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in pediatrics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it, 18 citations in OpenAlex.

  1. Sirolimus treatment for paediatric head and neck lymphatic malformations: a systematic review.European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery · 2023
    Pooled it
  2. A real-world study of sirolimus in the treatment of pediatric head and neck lymphatic malformations.Journal of vascular surgery. Venous and lymphatic disorders · 2025
    Article
  3. [Lymphatic malformations in childhood and adolescence].Radiologie (Heidelberg, Germany) · 2025
    Article
  4. Infantile hemangioma: the common and enigmatic vascular tumor.The Journal of clinical investigation · 2024
    Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 8 countries.

Annegret HolmDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Maroeska Te LooVASCERN VASCA European Reference Centre, Paris, France.
Leo Schultze KoolVASCERN VASCA European Reference Centre, Paris, France.
Päivi SalminenVASCERN VASCA European Reference Centre, Paris, France.
Veronica CelisSant Joan de Déu Hospital, Barcelona, Spain.
Eulalia BaselgaSant Joan de Déu Hospital, Barcelona, Spain.
Sophie DuignanVASCERN VASCA European Reference Centre, Paris, France.
Veronika DvorakovaVASCERN VASCA European Reference Centre, Paris, France.
Alan D IrvineVASCERN VASCA European Reference Centre, Paris, France.
Laurence M BoonVASCERN VASCA European Reference Centre, Paris, France.
Miikka VikkulaVASCERN VASCA European Reference Centre, Paris, France.
Nader GhaffarpourVASCERN VASCA European Reference Centre, Paris, France.
Charlotte M NiemeyerDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Jochen RösslerDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Friedrich G KappDivision of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Children's Health Ireland at Crumlin · IECliniques Universitaires Saint-Luc · BEHospital Sant Joan de Déu Barcelona · ESUniversity of Freiburg · DEKarolinska University Hospital · SERadboud University Medical Center · NLRadboud University Nijmegen · NLTrinity College Dublin · IEUniversity Hospital of Bern · CHUniversity Medical Center Freiburg · DEUniversity of Helsinki · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Extensive lymphatic malformations (LMs) of the head and neck region may require tracheostomy to secure the airway. Treatment of these life-threatening LMs is usually multimodal and includes sclerotherapy and surgery, among others. Recently, systemic therapy with sirolimus has been introduced as an effective treatment for venous and lymphatic malformations; its efficacy and safety profile in patients with extensive LM requiring tracheostomy are, however, as yet not fully known. We performed a retrospective, multicenter review and identified 13 patients with an extensive LM of the head and neck region, who previously underwent placement of tracheostomy and subsequently received sirolimus treatment with the aim to improve the local respiratory situation and remove the tracheostomy. Under sirolimus therapy, tracheostomy could be reversed in 8/13 (62%) patients, a further 2/13 (15%) patients improved markedly, and removal of the tracheostomy was planned at the time of writing, while 3/13 (23%) patients showed insufficient or absent response to sirolimus, rendering tracheostomy reversal not feasible. The median duration of sirolimus treatment until removal of tracheostomy was 18 months (range, 8 months to 5.6 years). Adverse events of sirolimus therapy were common [10/13 (77%) patients], yet the majority of these were mild [9/10 (90%) patients] and only one severe adverse event was recorded, with ulceration and necrosis at a catheter insertion site. In conclusion, sirolimus can be considered an effective and safe salvage treatment in patients with extensive LM even after placement of a tracheostomy, as closure of the latter was possible in the majority of patients (62%) of our retrospective cohort. A better understanding of when to start sirolimus therapy, of the duration of treatment, and of factors allowing the prediction of treatment response will require further investigation.

Indexed as

lymphatic malformationrapamycinsirolimustracheostomatracheostomyvascular anomaly

Identifiers

PMID34660476
PMCPMC8515018
OpenAlexW3204331723

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.